Pedro Rosa-Neto

• Université McGill

• Longitudinal neuroimaging of disease progression and treatment in rodent models of Alzheimer's Disease ( 2016/17-2020/21 ) CO
• Toward a better understanding of the impact of vascular health on Alzheimer's disease pathology and clinical expression ( 2016/17-2020/21 ) CO
• Role of HMG CoA reductase protective and risk variants in the pathophysiology and treatment of sporadic Alzheimer's disease ( 2017/18-2020/21 ) CO
• Interactions between pathophysiological processes as drivers of clinical progression in Alzheimer's disease ( 2017/18-2020/21 ) PI
• Diagnostic Biomarkers for pre-dementia Alzheimer Disease ( 2012/13-2016/17 ) CO

Serge G Gauthier

• Université McGill

• Toward a better understanding of the impact of vascular health on Alzheimer's disease pathology and clinical expression ( 2016/17-2020/21 ) CO
• Interactions between pathophysiological processes as drivers of clinical progression in Alzheimer's disease ( 2017/18-2020/21 ) CO
• Diagnostic Biomarkers for pre-dementia Alzheimer Disease ( 2012/13-2016/17 ) PI
• Relation between structural brain imaging and cognition in mixed and vascular mils cognitive impairment ( 2010/11 ) CO
• Understanding cognitive changes in mild cognitive impairment: Neuropsychological and neuroimaging studies ( 2010/11-2011/12 ) CO

Sandra E Black

• Sunnybrook Health Sciences Centre

• Aberrant phospholipid and sphingolipid metabolism is a primary and targetable pathology in Alzheimer Disease ( 2014/15-2018/19 ) CO
• Phase Two of the Canadian Consortium on Neurodegeneration in Aging ( 2019/20-2020/21 ) PI
• A multi-centre, double-blind, randomized, controlled trial compaing different regimens of the antibiotics doxycycline and rifampin for treatment of Alzheimer's disease with an open-label extension - DARAD ( 2010/11-2011/12 ) CO
• Brain degeneration and regeneration in preclinical models of Alzheimer's disease ( 2014/15-2019/20 ) CO
• In Vivo Brain Mapping in the Dementias: A Longitudinal Brain-Behaviour Study With a Focus on interactions of Alzheimer's and Cerebrovascular Disease ( 2010/11-2013/14 ) PI

Ging-Yuek R Hsiung

• Université de la Colombie-Britannique

• Novel Diagnostic Methods for Imaging Amyloid Beta in the eye in association with alzheimer's disease ( 2012/13-2014/15 ) CO
• Genetic epidemiology of dementias: genome-wide association study and gene-environment interactions analysis ( 2010/11-2011/12 ) PI
• Diagnostic Biomarkers for pre-dementia Alzheimer Disease ( 2012/13-2016/17 ) CO
• Translational Genetics Research in Dementia ( 2012/13-2014/15 ) PI
• Novel non-invasive imaging of amyloid in the retina of the eye as a predictor of amyloid in the brain in Alzheimer's disease ( 2016/17-2018/19 ) PI

Sylvie N Belleville

• Université de Montréal

• Maladie d'Alzheimer : Stratégies gouvernementales et recherche ( 2011/12 ) PI
• Relation between structural brain imaging and cognition in mixed and vascular mils cognitive impairment ( 2010/11 ) PI
• Phase Two of the Canadian Consortium on Neurodegeneration in Aging ( 2019/20-2020/21 ) PI
• Understanding cognitive changes in mild cognitive impairment: Neuropsychological and neuroimaging studies ( 2010/11-2011/12 ) PI
• Knowledge Translation that educates the public about signs and symptoms of AD ( 2011/12 ) CO

Howard M Chertkow

• Baycrest Health Sciences

• Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease subtypes. ( 2015/16-2020/21 ) PI
• Diagnosis, localization, and treatment of semantic memory impairment in Alzheimer's Disease ( 2010/11-2011/12 ) PI
• Establishing prognostic subgroups in mild cognitive impairment ( 2010/11-2011/12 ) PI
• The Canadian ADNI BraIn Donation and Neuropathology Network (CABIN) - Optimizing Canadian Participation in the Neuropathology Program of ADNI ( 2017/18-2020/21 ) PI
• The impact of beta-amyloid burden on cognition in normal aging ( 2011/12 ) CO

John C Breitner

• Université McGill

• Longitudinal neuroimaging of disease progression and treatment in rodent models of Alzheimer's Disease ( 2016/17-2020/21 ) CO
• Toward a better understanding of the impact of vascular health on Alzheimer's disease pathology and clinical expression ( 2016/17-2020/21 ) CO
• Role of HMG CoA reductase protective and risk variants in the pathophysiology and treatment of sporadic Alzheimer's disease ( 2017/18-2020/21 ) CO
• Imaging-genetics biomarkers for disease risk in Alzheimer's Disease. ( 2015/16-2019/20 ) CO
• Preventing the progression of Alzheimer's disease pathology by targeting the effects of lifestyle factors and personality traits. ( 2019/20-2020/21 ) CO

Paul E Fraser

• Université de Toronto

• Presenilin complex components and the gamma-secretase in Alzheimer's Disease ( 2010/11 ) PI
• Alzheimer Disease Pathobiology and Mechanisms of Neurodegeneration ( 2011/12-2016/17 ) PI
• The role of a novel APP-interacting, pro-apoptotic protein in Alzheimer's disease ( 2011/12-2015/16 ) PI
• SUMOylation Pathways in Alzheimer Disease and Their Therapeutic Implications ( 2020/21 ) PI
• Investigation of the roles of GSK-3 isoforms in mediating Abeta, tau and insulin related Alzheimer-like synaptic, cholinergic impairments ( 2012/13-2016/17 ) CO

David Westaway

• Université de l'Alberta

• Discovery of biomarkers of alzheimer's disease using comprehensive and quantitative metabolomics ( 2012/13-2014/15 ) CO
• Role of lysosomal enzymes cathepsins B and D in neuronal vulnerability: potential implications in Alzheimer's disease pathology ( 2018/19-2020/21 ) CO
• Discovery of biomarkers of alzheimer's disease using comprehensive and quantitative metabolomics ( 2012/13-2013/14 ) CO
• PrP N-terminal sequences and biological endpoints in Prion and Alzheimer's Disease ( 2012/13-2017/18 ) PI
• Molecular switch function in a prion protein; control of pathways leading to pathogenesis or disease remediation ( 2019/20-2020/21 ) PI

Bojana Stefanovic

• Sunnybrook Health Sciences Centre

• Transdifferentiation of astrocytes into neurons to improve neuronal network function in Alzheimer's disease. ( 2018/19-2020/21 ) PI
• Enhancing vascular remodeling in Alzheimer's disease following covert stroke ( 2015/16-2020/21 ) CO
• In Vivo Brain Mapping in the Dementias: A Longitudinal Brain-Behaviour Study With a Focus on interactions of Alzheimer's and Cerebrovascular Disease ( 2010/11-2013/14 ) CO
• Contribution of Mid-life Comorbidities to Alzheimer's Disease ( 2017/18-2020/21 ) PI
• Towards functional imaging biomarkers of Alzheimer's Disease ( 2010/11-2012/13 ) CO